NBW Capital LLC reduced its position in HealthEquity, Inc. (NASDAQ:HQY – Free Report) by 1.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 86,615 shares of the company’s stock after selling 1,033 shares during the period. NBW Capital LLC owned 0.10% of HealthEquity worth $5,743,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. McGlone Suttner Wealth Management Inc. bought a new stake in shares of HealthEquity during the fourth quarter valued at about $29,000. Castleview Partners LLC bought a new stake in shares of HealthEquity during the second quarter valued at about $39,000. Lazard Asset Management LLC increased its position in shares of HealthEquity by 117.9% during the third quarter. Lazard Asset Management LLC now owns 549 shares of the company’s stock valued at $40,000 after buying an additional 297 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in shares of HealthEquity during the third quarter valued at about $41,000. Finally, Fifth Third Bancorp increased its position in shares of HealthEquity by 36.5% during the third quarter. Fifth Third Bancorp now owns 602 shares of the company’s stock valued at $44,000 after buying an additional 161 shares during the period. 99.55% of the stock is currently owned by institutional investors.
HealthEquity Price Performance
HQY traded up $1.03 during midday trading on Thursday, hitting $80.90. The stock had a trading volume of 188,400 shares, compared to its average volume of 600,709. The company has a market cap of $6.94 billion, a P/E ratio of 127.03, a price-to-earnings-growth ratio of 1.31 and a beta of 0.53. The business has a fifty day moving average of $81.02 and a 200 day moving average of $74.17. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.76 and a current ratio of 4.76. HealthEquity, Inc. has a 1 year low of $48.86 and a 1 year high of $84.49.
Analysts Set New Price Targets
Several research analysts have recently commented on the company. Barclays boosted their price objective on HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. KeyCorp boosted their price objective on HealthEquity from $85.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Bank of America boosted their price objective on HealthEquity from $93.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. BTIG Research boosted their price objective on HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Finally, JMP Securities assumed coverage on HealthEquity in a report on Thursday, April 4th. They set a “mkt outperform” rating and a $101.00 price objective for the company. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, HealthEquity presently has an average rating of “Moderate Buy” and a consensus price target of $96.17.
Read Our Latest Research Report on HealthEquity
Insider Buying and Selling at HealthEquity
In other HealthEquity news, EVP Delano Ladd sold 2,499 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $80.00, for a total value of $199,920.00. Following the completion of the sale, the executive vice president now owns 49,996 shares in the company, valued at $3,999,680. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other HealthEquity news, EVP Delano Ladd sold 2,499 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $80.00, for a total value of $199,920.00. Following the completion of the sale, the executive vice president now owns 49,996 shares in the company, valued at $3,999,680. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the company’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total value of $2,694,784.65. Following the transaction, the chief executive officer now owns 126,635 shares of the company’s stock, valued at approximately $10,106,739.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,322 shares of company stock worth $5,682,895. 2.70% of the stock is currently owned by insiders.
HealthEquity Profile
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading
- Five stocks we like better than HealthEquity
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Comprehensive PepsiCo Stock Analysis
- How to Capture the Benefits of Dividend Increases
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Ride Out The Recession With These Dividend KingsĀ
- Bear Market Funds to Watch This Year
Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY – Free Report).
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.